PrEP

Increased use of and confidence in antiretroviral PrEP for prevention of HIV found

More gay and bisexual men are using HIV pre-exposure prophylaxis (PrEP) with increased confidence in the benefits of HIV treatment for prevention, according to a UNSW study. Significantly more gay and bisexual men are using the antiretroviral drug PrEP to prevent HIV infection, according to the latest report from the PrEPARE Project. The national online

Increased use of and confidence in antiretroviral PrEP for prevention of HIV found Read More »

Drugmaker Gilead Is Making HIV Prevention Meds More Accessible

Earlier this month, pharmaceutical company Gilead Sciences announced that it will donate enough HIV prevention drug Truvada to the Centers for Disease Control and Prevention (CDC) to benefit 200,000 people at risk for HIV. While news of the announcement was met positively, it also came ahead of some other negative headlines surrounding the drugmaker, coupled

Drugmaker Gilead Is Making HIV Prevention Meds More Accessible Read More »

Study confirms no transmissions with undetectable HIV

The largest treatment-as-prevention study for gay and bisexual men confirms that people on antiretroviral therapy with undetectable viral load do not transmit HIV. Results from the PARTNER2 study, which enrolled nearly 1,000 mixed-status gay male couples in 14 European countries, saw no genetically linked HIV transmissions when the positive partner was on effective treatment. “PARTNER2

Study confirms no transmissions with undetectable HIV Read More »

One year of preventing new HIV infections throughout B.C.

Thousands of people at the highest risk of acquiring HIV in B.C. are benefiting after a successful year since government expanded coverage for HIV pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP). “Since expanding access to PrEP on Jan. 1, 2018, nearly 3,300 people have been prescribed the potentially life-saving medications. It is positive to see

One year of preventing new HIV infections throughout B.C. Read More »

Scroll to Top

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below